[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.155.6. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
November 1992

Molecular Surgery for Cancer

Author Affiliations

From the Departments of Thoracic Surgery and Tumor Biology, The University of Texas M. D. Anderson Cancer Center, Houston.

Arch Surg. 1992;127(11):1298-1302. doi:10.1001/archsurg.1992.01420110040010
Abstract

• Advances in the understanding of the process of carcinogenesis may allow prevention, diagnosis, and treatment of cancer to be approached at the molecular level. Studies in our laboratory show that growth factors (transforming growth factor alpha), dominant oncogenes (HER-2/erb B2 and K-ras), and tumor suppressor genes (p53) are functionally important in the maintenance of the malignant phenotype of human non—small-cell lung cancer cells. Application of these findings to clinical problems include the identification of p53 mutations as markers for malignant change in Barrett's epithelium, the use of discordant p53 mutations to diagnose second primary malignant neoplasms in patients with head and neck cancer, and the potential for therapy by the reversal of genetic lesions.

(Arch Surg. 1992;127:1298-1302)

×